Molecular Imaging Program

Director
Peter L. Choyke, M.D., F.A.C.R.

The goal of the Molecular Imaging Program (MIP) is to develop targeted imaging methods that accelerate the development of cancer therapies. The MIP is focused on the development and translation of in vivo molecular imaging agents for early detection and monitoring. Given the high risks and high costs of conducting research in this field, the MIP is well positioned to address challenges that the field of molecular imaging faces.

Molecular Imaging Clinic
The Molecular Imaging Clinic is located in the NIH Clinical Center (Building 10) on the main NIH campus in Bethesda, MD. We investigate diagnostic imaging agents that employ nuclear, optical or magnetic resonance reporters in human subjects. Currently, there are 12 active human protocols. This effort is supported by a network of chemistry laboratories, including the Imaging Probe Development Center, National Heart Lung and Blood Institute; the Cancer Imaging Program's Scientific Support Laboratory, NCI Division of Cancer Diagnosis and Treatment; and the PET Department and Radiolabeling Laboratory of the NIH Clinical Center. The Program's preclinical research section consists of three labs.

Targeted Radionuclide Therapy Section
Led by Frank I. Lin, M.D., the Targeted Radionuclide Therapy (TRT) Section is dedicated to bringing promising TRT agents from the laboratory into patients on clinical trials, ranging from First-in-Human Phase 1 trials to collaborating on international multicenter Phase 3  trials. The TRT section also has expertise in  the pre-clinical development of promising future TRTs, with a special interest in small molecule agents and high LET radionuclides such as alpha or Auger-electron-emitting radioisotopes

Laboratory of Molecular Radiotherapy

Led by Freddy E. Escorcia, M.D., Ph.D., The Laboratory of Molecular Radiotherapy is focused on engineering tumor-selective molecular probes for human cancers, with particular interest in hepatobiliary malignancies. The lab combines bioinformatics, bioconjugate chemistry, radiochemistry, molecular biology, and animal models to identify tumor-selective molecules then engineer and screen agents for subsequent use in cancer imaging and therapy. Current cross-institute efforts involve the targeting of a hepatocellular carcinoma selective markers for ultimate use in imaging-based screening of high risk patient populations, detection of early recurrences, and therapy selection.

Laboratory of Theranostics
Led by Hisataka Kobayashi, M.D., Ph.D., this lab has developed activatable optical contrast agents. Additionally, he has identified antibody-photosensitizer conjugates (APCs) that produce highly targeted necrotic cell death. This has been termed "photoimmunotherapy" and will shortly enter clinical trials. We are also developing a variety of radionuclide-targeted imaging agents for clinical translation.

Laboratory of Radiopharmaceutical Development
Led by Elaine Jagoda, M.S., this laboratory's current portfolio includes molecular imaging agents for c-MET, mesothelin, ACE inhibitors and TEM8 associated with angiogenesis.

Laboratory of Cellular Therapeutics
Led by Noriko Sato, M.D., Ph.D., this group aims to develop and use imaging techniques to uncover the fate of cells administered as cellular therapies and to better understand the mechanism of immune activation.

Comparative Oncology Program
Led by Amy LeBlanc DVM, this program uses naturally occurring cancers seen in pet animals to better understand the biology of cancer, with the goal of accelerating drug and imaging agent development for humans. 

 

 

 


There are no Open Positions at this time, check back again later.


About

The goal of the Molecular Imaging Program (MIP) is to develop targeted imaging methods that accelerate the development of cancer therapies. The MIP is focused on the development and translation of in vivo molecular imaging agents for early detection and monitoring. Given the high risks and high costs of conducting research in this field, the MIP is well positioned to address challenges that the field of molecular imaging faces.

Molecular Imaging Clinic
The Molecular Imaging Clinic is located in the NIH Clinical Center (Building 10) on the main NIH campus in Bethesda, MD. We investigate diagnostic imaging agents that employ nuclear, optical or magnetic resonance reporters in human subjects. Currently, there are 12 active human protocols. This effort is supported by a network of chemistry laboratories, including the Imaging Probe Development Center, National Heart Lung and Blood Institute; the Cancer Imaging Program's Scientific Support Laboratory, NCI Division of Cancer Diagnosis and Treatment; and the PET Department and Radiolabeling Laboratory of the NIH Clinical Center. The Program's preclinical research section consists of three labs.

Targeted Radionuclide Therapy Section
Led by Frank I. Lin, M.D., the Targeted Radionuclide Therapy (TRT) Section is dedicated to bringing promising TRT agents from the laboratory into patients on clinical trials, ranging from First-in-Human Phase 1 trials to collaborating on international multicenter Phase 3  trials. The TRT section also has expertise in  the pre-clinical development of promising future TRTs, with a special interest in small molecule agents and high LET radionuclides such as alpha or Auger-electron-emitting radioisotopes

Laboratory of Molecular Radiotherapy

Led by Freddy E. Escorcia, M.D., Ph.D., The Laboratory of Molecular Radiotherapy is focused on engineering tumor-selective molecular probes for human cancers, with particular interest in hepatobiliary malignancies. The lab combines bioinformatics, bioconjugate chemistry, radiochemistry, molecular biology, and animal models to identify tumor-selective molecules then engineer and screen agents for subsequent use in cancer imaging and therapy. Current cross-institute efforts involve the targeting of a hepatocellular carcinoma selective markers for ultimate use in imaging-based screening of high risk patient populations, detection of early recurrences, and therapy selection.

Laboratory of Theranostics
Led by Hisataka Kobayashi, M.D., Ph.D., this lab has developed activatable optical contrast agents. Additionally, he has identified antibody-photosensitizer conjugates (APCs) that produce highly targeted necrotic cell death. This has been termed "photoimmunotherapy" and will shortly enter clinical trials. We are also developing a variety of radionuclide-targeted imaging agents for clinical translation.

Laboratory of Radiopharmaceutical Development
Led by Elaine Jagoda, M.S., this laboratory's current portfolio includes molecular imaging agents for c-MET, mesothelin, ACE inhibitors and TEM8 associated with angiogenesis.

Laboratory of Cellular Therapeutics
Led by Noriko Sato, M.D., Ph.D., this group aims to develop and use imaging techniques to uncover the fate of cells administered as cellular therapies and to better understand the mechanism of immune activation.

Comparative Oncology Program
Led by Amy LeBlanc DVM, this program uses naturally occurring cancers seen in pet animals to better understand the biology of cancer, with the goal of accelerating drug and imaging agent development for humans. 

 

 

 

Clinical Trials

PI & Key Staff

Positions


There are no Open Positions at this time, check back again later.


Contact Info

Molecular Imaging Program
Center for Cancer Research
National Cancer Institute
Building 10, Room B3B69F
Bethesda, MD 20892-1088
Ph: 240-858-3071
Research Nurse
240-760-6095
Technical Lab Manager
240-858-3087